Leronlimab - CytoDyn

Drug Profile

Leronlimab - CytoDyn

Alternative Names: PA-14; PRO-140

Latest Information Update: 12 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Progenics Pharmaceuticals
  • Developer CytoDyn; Progenics Pharmaceuticals; The Scripps Research Institute
  • Class Antineoplastics; Antiretrovirals; Monoclonal antibodies
  • Mechanism of Action CCR5 receptor antagonists; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections
  • Phase II/III HIV-1 infections
  • Phase II Graft-versus-host disease
  • Preclinical Breast cancer; Colorectal cancer; Prostate cancer

Most Recent Events

  • 05 Nov 2018 CytoDyn expects to file for breakthrough therapy designation for Breast cancer
  • 05 Nov 2018 CytoDyn files an IND application with the USFDA in USA for Breast Cancer
  • 10 Oct 2018 CytoDyn plans a pivotal clinical trial for HIV-1 infections (Monotherapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top